COMP <GO>
SRRK vs IMVT // RETURN ON INVESTED CAPITAL (ROIC)
Scholar Rock Holding Corporation (NASDAQ) VS. Immunovant Inc. (NASDAQ) • 15-METRIC TALLY: SRRK 4
— IMVT 3
■ METRIC PARITY
LAST: $43.98 (+2.49%) • MKT CAP: $5.23B
roic
-35.00%
LAST: $29.04 (+2.22%) • MKT CAP: $5.87B
roic
-35.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SRRK VS. IMVT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SRRK | IMVT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.59% | -6.65% | +1.06 | SRRK | /fcf-yield <GO> |
| Operating Margin | — | -36.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -29.50% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 7.70% | 9.90% | -2.20 | IMVT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.67 | 26.00 | -12.33 | IMVT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.5 | 36.4 | +8.10 | SRRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 0.98 | +0.04 | SRRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 36.0x | -4.00 | SRRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.23B | $5.87B | -$642.4M | IMVT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SRRK REV | IMVT REV | SRRK GROSS % | IMVT GROSS % | SRRK FCF | IMVT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.08B | $1.67B | — | — | -$300.6M | -$407.3M |
| FY 2024 | $705.8M | $1.37B | — | — | -$201.0M | -$376.6M |
| FY 2023 | $479.6M | $856.8M | — | — | -$145.2M | -$214.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SRRK // BETA 1.02
IMVT // BETA 0.98